Just caught wind that BioRestorative's CEO Lance Alstodt did an interview on Benzinga last June talking about their stem cell therapy work. The company's been quietly building out some interesting stuff in the regenerative medicine space - they've got BRTX-100 for back pain treatment and this ThermoStem program targeting obesity using brown fat cells. Pretty wild concept honestly.

What's interesting is the hedge fund activity around $BRTX. Some big names like Citadel and Renaissance completely bailed out in 2024-2025, but Morgan Stanley and Vanguard actually added positions recently. Mixed signals there. The company's in Phase 2 trials for their lead therapy, so it's still early stage but they do have FDA clearance to test cervical spine applications too.

They're also running a cosmeceutical side business with some kind of biotech serum for skincare. Lance Alstodt and the team seem to be positioning this as a multi-pronged approach - clinical therapeutics plus commercial cosmetic products. The usual biotech risk warnings apply of course - long road to commercialization, regulatory uncertainty, all that. But if the science pans out, could be something. Definitely one to watch if you're into early-stage biotech plays.